MicroRNA作为检测小睾丸肿块恶性肿瘤的液体生物标志物。

IF 9.3 1区 医学 Q1 ONCOLOGY
Julian Chavarriaga, Carley Langleben, João Lobo, Lucia Nappi, George M Yousef, Gizem Ozcan, Nastaran Khazamipour, Nuno Tiago Tavares, Ioannis Prassas, Lampros Dimitrakopoulos, Xiaotian Yuan, Adam Bobrowski, Susan Prendeville, Lynn Anson-Cartwright, Carmen Jeronimo, Keith Jarvi, Martin O'Malley, Ricardo Leão, Katherine Lajkosz, Robert J Hamilton
{"title":"MicroRNA作为检测小睾丸肿块恶性肿瘤的液体生物标志物。","authors":"Julian Chavarriaga, Carley Langleben, João Lobo, Lucia Nappi, George M Yousef, Gizem Ozcan, Nastaran Khazamipour, Nuno Tiago Tavares, Ioannis Prassas, Lampros Dimitrakopoulos, Xiaotian Yuan, Adam Bobrowski, Susan Prendeville, Lynn Anson-Cartwright, Carmen Jeronimo, Keith Jarvi, Martin O'Malley, Ricardo Leão, Katherine Lajkosz, Robert J Hamilton","doi":"10.1016/j.euo.2025.08.004","DOIUrl":null,"url":null,"abstract":"<p><strong>Background and objective: </strong>Approximately 1-4% of individuals undergoing scrotal ultrasound are found with incidental small (≤2 cm) testicular masses (STMs), with the vast majority being benign (∼13-21% malignant). This study explores the potential of microRNAs (miRNAs) as liquid biomarkers for predicting germ cell tumors (GCTs) in STMs.</p><p><strong>Methods: </strong>From 2009 to 2023, we identified patients with STMs who had banked serum/plasma prior to orchiectomy. Eligible samples were analyzed using different miRNA expression methods (reverse transcription quantitative polymerase chain reaction [RT-qPCR] and digital droplet polymerase chain reaction) and platforms across three research laboratory facilities (Portugal, Vancouver, and Toronto). The miRNA assays included 371a-3p, 372, 373, and 367. The primary objective was to evaluate the diagnostic accuracy of miR-371a-3p to predict the presence of testicular cancer using the area under the curve (AUC).</p><p><strong>Key findings and limitations: </strong>Our cohort included 61 patients: 37 patients with confirmed GCTs, 20 patients with benign histology, and four patients who had been on surveillance for >24 mo and were deemed to have benign STMs. Across all three laboratories, miR-371a-3p consistently outperformed all the miRNAs, with the other miRNAs proving uninformative. Extraction from plasma and an RT-qPCR analysis (Vancouver laboratory) proved best, with sensitivity of 87% and specificity of 91%, translating into an AUC of 0.93. The receiver operating characteristic scores for the other two laboratories were 0.77 and 0.73 for Portugal and Toronto, respectively. This single-center study is limited by a potential selection bias and fewer evaluable samples due to technical and logistical issues.</p><p><strong>Conclusions and clinical implications: </strong>This is the largest series of STMs with banked blood/serum to date. Among the miRNAs, miR-371a-3p was found to be sensitive and specific for detecting the presence of GCTs in STMs. Plasma with an RT-qPCR approach proved to be a superior method of analysis.</p>","PeriodicalId":12256,"journal":{"name":"European urology oncology","volume":" ","pages":""},"PeriodicalIF":9.3000,"publicationDate":"2025-09-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"MicroRNA as a Liquid Biomarker to Detect Malignancy in Small Testicular Masses.\",\"authors\":\"Julian Chavarriaga, Carley Langleben, João Lobo, Lucia Nappi, George M Yousef, Gizem Ozcan, Nastaran Khazamipour, Nuno Tiago Tavares, Ioannis Prassas, Lampros Dimitrakopoulos, Xiaotian Yuan, Adam Bobrowski, Susan Prendeville, Lynn Anson-Cartwright, Carmen Jeronimo, Keith Jarvi, Martin O'Malley, Ricardo Leão, Katherine Lajkosz, Robert J Hamilton\",\"doi\":\"10.1016/j.euo.2025.08.004\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background and objective: </strong>Approximately 1-4% of individuals undergoing scrotal ultrasound are found with incidental small (≤2 cm) testicular masses (STMs), with the vast majority being benign (∼13-21% malignant). This study explores the potential of microRNAs (miRNAs) as liquid biomarkers for predicting germ cell tumors (GCTs) in STMs.</p><p><strong>Methods: </strong>From 2009 to 2023, we identified patients with STMs who had banked serum/plasma prior to orchiectomy. Eligible samples were analyzed using different miRNA expression methods (reverse transcription quantitative polymerase chain reaction [RT-qPCR] and digital droplet polymerase chain reaction) and platforms across three research laboratory facilities (Portugal, Vancouver, and Toronto). The miRNA assays included 371a-3p, 372, 373, and 367. The primary objective was to evaluate the diagnostic accuracy of miR-371a-3p to predict the presence of testicular cancer using the area under the curve (AUC).</p><p><strong>Key findings and limitations: </strong>Our cohort included 61 patients: 37 patients with confirmed GCTs, 20 patients with benign histology, and four patients who had been on surveillance for >24 mo and were deemed to have benign STMs. Across all three laboratories, miR-371a-3p consistently outperformed all the miRNAs, with the other miRNAs proving uninformative. Extraction from plasma and an RT-qPCR analysis (Vancouver laboratory) proved best, with sensitivity of 87% and specificity of 91%, translating into an AUC of 0.93. The receiver operating characteristic scores for the other two laboratories were 0.77 and 0.73 for Portugal and Toronto, respectively. This single-center study is limited by a potential selection bias and fewer evaluable samples due to technical and logistical issues.</p><p><strong>Conclusions and clinical implications: </strong>This is the largest series of STMs with banked blood/serum to date. Among the miRNAs, miR-371a-3p was found to be sensitive and specific for detecting the presence of GCTs in STMs. Plasma with an RT-qPCR approach proved to be a superior method of analysis.</p>\",\"PeriodicalId\":12256,\"journal\":{\"name\":\"European urology oncology\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":9.3000,\"publicationDate\":\"2025-09-24\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"European urology oncology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1016/j.euo.2025.08.004\",\"RegionNum\":1,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"European urology oncology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.euo.2025.08.004","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0

摘要

背景和目的:在接受阴囊超声检查的患者中,约有1-4%的患者发现偶发的睾丸小肿块(≤2厘米),其中绝大多数为良性(约13-21%为恶性)。本研究探讨了microRNAs (miRNAs)作为预测STMs生殖细胞肿瘤(gct)的液体生物标志物的潜力。方法:从2009年到2023年,我们确定了在睾丸切除术前有血清/血浆库的STMs患者。在三个研究实验室设施(葡萄牙、温哥华和多伦多)使用不同的miRNA表达方法(逆转录定量聚合酶链反应[RT-qPCR]和数字液滴聚合酶链反应)和平台分析符合条件的样本。miRNA检测包括371a-3p、372、373和367。主要目的是评估miR-371a-3p使用曲线下面积(AUC)预测睾丸癌存在的诊断准确性。主要发现和局限性:我们的队列包括61例患者:37例确诊的gct患者,20例组织学为良性的患者,4例已监测bbbb24个月并被认为是良性STMs的患者。在所有三个实验室中,miR-371a-3p始终优于所有mirna,而其他mirna被证明没有提供信息。从血浆中提取和RT-qPCR分析(温哥华实验室)证明是最好的,灵敏度为87%,特异性为91%,转化为AUC为0.93。葡萄牙和多伦多的其他两个实验室的接收者操作特征得分分别为0.77和0.73。由于技术和后勤问题,该单中心研究受到潜在选择偏差和可评估样本较少的限制。结论和临床意义:这是迄今为止最大的STMs血液/血清库系列。在这些mirna中,发现miR-371a-3p对于检测STMs中gct的存在具有敏感性和特异性。血浆RT-qPCR方法被证明是一种较好的分析方法。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
MicroRNA as a Liquid Biomarker to Detect Malignancy in Small Testicular Masses.

Background and objective: Approximately 1-4% of individuals undergoing scrotal ultrasound are found with incidental small (≤2 cm) testicular masses (STMs), with the vast majority being benign (∼13-21% malignant). This study explores the potential of microRNAs (miRNAs) as liquid biomarkers for predicting germ cell tumors (GCTs) in STMs.

Methods: From 2009 to 2023, we identified patients with STMs who had banked serum/plasma prior to orchiectomy. Eligible samples were analyzed using different miRNA expression methods (reverse transcription quantitative polymerase chain reaction [RT-qPCR] and digital droplet polymerase chain reaction) and platforms across three research laboratory facilities (Portugal, Vancouver, and Toronto). The miRNA assays included 371a-3p, 372, 373, and 367. The primary objective was to evaluate the diagnostic accuracy of miR-371a-3p to predict the presence of testicular cancer using the area under the curve (AUC).

Key findings and limitations: Our cohort included 61 patients: 37 patients with confirmed GCTs, 20 patients with benign histology, and four patients who had been on surveillance for >24 mo and were deemed to have benign STMs. Across all three laboratories, miR-371a-3p consistently outperformed all the miRNAs, with the other miRNAs proving uninformative. Extraction from plasma and an RT-qPCR analysis (Vancouver laboratory) proved best, with sensitivity of 87% and specificity of 91%, translating into an AUC of 0.93. The receiver operating characteristic scores for the other two laboratories were 0.77 and 0.73 for Portugal and Toronto, respectively. This single-center study is limited by a potential selection bias and fewer evaluable samples due to technical and logistical issues.

Conclusions and clinical implications: This is the largest series of STMs with banked blood/serum to date. Among the miRNAs, miR-371a-3p was found to be sensitive and specific for detecting the presence of GCTs in STMs. Plasma with an RT-qPCR approach proved to be a superior method of analysis.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
CiteScore
15.50
自引率
2.40%
发文量
128
审稿时长
20 days
期刊介绍: Journal Name: European Urology Oncology Affiliation: Official Journal of the European Association of Urology Focus: First official publication of the EAU fully devoted to the study of genitourinary malignancies Aims to deliver high-quality research Content: Includes original articles, opinion piece editorials, and invited reviews Covers clinical, basic, and translational research Publication Frequency: Six times a year in electronic format
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信